MACROPROLACTIN

The MACROPROLACTIN screening test differentiates biologically inactive macroprolactin from the monomeric (active) form of prolactin. Using methods such as PEG precipitation or immunoassay fractionation, the test quantifies total prolactin and the PEG‑precipitable fraction to determine prolactin recovery and the likely clinical significance.

This screening is important because macroprolactin can cause elevated total prolactin results without clinical symptoms of hyperprolactinemia, leading to unnecessary imaging or treatment. It is commonly used in fertility workups, in patients with incidental or mild prolactin elevations, and whenever clinicians need to confirm whether elevated prolactin is truly biologically active; at‑home sample collection is available across Dubai and the UAE for convenient access.

• Total Prolactin
• Macroprolactin (PEG‑precipitable fraction)
• Free (Monomeric) Prolactin
• Prolactin Recovery (%) after PEG precipitation

• Persistently elevated total prolactin on routine labs
• Infertility or subfertility assessment
• Unexplained galactorrhea or menstrual irregularities
• Before ordering pituitary MRI or starting dopamine‑agonist therapy
• Men with mild hyperprolactinemia and sexual dysfunction

• Accurate differentiation of macroprolactin versus active prolactin
• Reduces unnecessary imaging and inappropriate treatment
• Supports fertility and endocrine clinical decision‑making
• Convenient at‑home blood collection across Dubai and the UAE
• Clear reporting to guide follow‑up or specialist referral

• At‑home venous blood collection by a certified phlebotomist
• Prefer morning sample (ideally before 10:00 AM) after 30 minutes rest
• Avoid strenuous exercise and nipple stimulation prior to sampling
• Inform your provider about medications that can raise prolactin (e.g., antipsychotics, metoclopramide)